News

This new data from ACR 2023 suggests that the guidelines on a healthy diet predominantly based on plants have been confirmed with regard to incident gout.

Receipt of RZV was not associated with an increased risk of incident gout among more than 1,000 adults ≥ 65 years of age who received at least 1 dose of the 2-dose vaccine regimen.

This news from the FDA followed a resubmission after the FDA’s complete response letter for the P2X3 receptor antagonist’s use in refractory chronic cough and unexplained cough.

Lifestyle habits including vegetable consumption and exercise were associated with Gout Impact Scale score.

This long-term data on dupilumab investigated both survival rates and rationale for treatment discontinuation.

Most ophthalmology teaching faculty noted their lack of awareness about available resources or training as a barrier, rather than a lack of time, perceived benefit, or funding.

Some racial minority groups face higher disease burdens and worse outcomes in rheumatoid arthritis, so it is important to ensure that clinical trials include representatives from these groups. Take this quiz to test your knowledge of efforts to ensure minorities are represented in clinical trials.

Chari Cohen, DrPH, MPH, discusses the current landscape of hepatitis B management and areas she sees room for development.

In this column, Katherine Saunders, MD, of Weill Cornell Medicine, provides perspective on the approval of tirzepatide for chronic weight management and what it might mean for patient access in the future.

At 16 weeks, patients treated with bimekizumab reported greater improvements in both mean spine pain and morning stiffness when compared with placebo. These improvements continued through week 52.

An analysis of the AI tool showed it could help translate complex ophthalmology research for various patient levels of comprehension.

An analysis of interest at matriculation and graduation suggests significant disparities, based on race and income, could be contributing to the diminishing workforce in ophthalmology.

At AAO 2023, Korobelnik provides insight into the efficacy and safety of aflibercept 8 mg in patients with nAMD observed over 2 years of the PULSAR study.

Sustained remission was observed in more patients receiving rituximab and concomitant avacopan compared with those treated with concomitant prednisone.

At AAO 2023, Kay shares insight into the topline results of the TEASE-1 study investigating the effect of gildeuretinol (ALK-001) on the inherited retinal disease.

In this data shown at ACR 2023, the URAT1 inhibitor known as AR882 showed promising phase 2b data for patients with gout.

Findings from a retrospective cohort study highlighted the impact of bariatric surgery on postoperative ocular disease incidence, reducing the risk of future ocular morbidity.

Household primary language was associated with vision screening, with children from non-English households exhibiting lower rates of pediatric vision screening.

The 3-year and 5-year renal survival rates did not exhibit significant changes, but IgAN's 10-year renal survival has shown gradual decreases since the 1990s.

New data shows one-quarter of patients with kidney disease associated with IBD progress to end-stage disease, with primary determinants including age and baseline eGFR.

During this segment of his interview, Dr. Kim went into the Harmony study data on safety of ADP101 presented at ACAAI as well as the implications of the research.

Investigators reported that AI programs such as LightGBM could potentially significantly benefit the diagnosis of Berger disease.

Advanced kidney disease, type 2 diabetes, and high risk of disease progression were prevalent among the cohort based on records collected from the HealthVerity database.

In this interview segment, Dr. Kim described some of the background and importance of the Harmony study data presented at ACAAI for patients with food allergy.

Per the FDA, Kilitch Healthcare India Limited voluntarily recalls 27 eye drop items, including those distributed by CVS, Rite Aid, and Target, due to potential safety issues.

Part 1 of the study evaluates reduction in urine protein: creatinine ratio, and part 2 of the study evaluates the number of patients achieving complete remission when on the bruton tyrosine kinase inhibitor for primary membranous nephropathy.

Results highlighted an association between socioeconomic deprivation and greater risk of progression to kidney failure in patients with IgAN.

Ahmad Masri, MD, MS, discusses new acoramidis data from the ATTRibute-CM trial at AHA 2023.

A post hoc analysis of the SCORED trial suggested the clinical benefit of sotagliflozin on heart failure and MACE-related outcomes in as early as 3 months in a high-risk population.

The most successful outcomes were observed in patients with at least 6 months of pegloticase therapy who promptly began oral therapy within 60 days.